Broker’s call: Symbiotec Pharmalab (Buy)

Madhya Pradesh-based Symbiotec Pharmalab Ltd (SPL) is an active pharmaceutical ingredients (API) company specializing in corticosteroids and steroidal hormones. The company operates at a global level, holding a significant share of the market. With a market share of 38.2% in corticosteroid APIs and 23.8% in steroidal hormone APIs, SPL is poised for growth.

The company's product portfolio is diverse, encompassing approximately 60 products available in both sterile and non-sterile formats. These products serve a wide range of customers, totaling over 200 clients across 40+ countries, including more than 150 export customers. SPL has been investing heavily in expanding its operations, with a capital expenditure of nearly ₹1,000 crore over the past three to four years.

This includes investments of ₹376 crore in complex injectables and ₹584 crore in contract development and manufacturing organizations (CDMO). Based on these factors, we are recommending a buy on SPL, with a price target of ₹1,570. This valuation is based on a price-to-estimated earnings ratio of 19x of FY29E EBITDA, which is projected to be ₹542.4 crore.

The company's potential for transition from traditional API production to a more complex API and CDMO model is promising. However, there are key concerns that need to be addressed, such as the ramp-up of new business verticals, regulatory and compliance risks, and customer concentration risks.